
IL-6 signaling | Barrier dysfunction | Angiogenesis | VEGF signaling | Diabetic retinopathy | Dry eye disease | Translational research

Shruti Sharma, MS, PhD
Associate Professor
Center for Biotechnology & Genomic Medicine
James and Jean Culver Vision Discovery Institute
Department of Ophthalmology
Medical College of Georgia at ǿմý
706-721-6522
Office: CA-4139 | Lab: CA-4132A
Jump to: Research Interests Projects Funding & Teaching Media Articles & Publications Graduate Students & Staff
The Shruti Sharma Lab employs molecular, cellular, and translational approaches to study diabetic retinopathy (DR) and dry eye disease (DED). The lab integrates in-vitro and in-vivo models to investigate mechanisms of inflammation, vascular dysfunction, and ocular surface damage. A major focus of our work is the role of interleukin-6 (IL-6) signaling, investigating 1) how the disruption of the “IL-6 cis-trans balance” in retinal Müller glial cells alters VEGF regulation, causing retinal neurovascular dysfunction, and 2) whether selective inhibition of IL-6 trans-signaling with sgp130Fc can reduce inflammation. In our DED research, we examine the osmoprotective potential of L-carnitine in preventing epithelial barrier disruption, inflammation, and ocular surface damage.
IL-6 is a pleiotropic cytokine with both anti- & pro-inflammatory roles. Our lab has
established that selectively inhibiting IL-6 trans-signaling with sgp130Fc can prevent
oxidative stress, inflammation, barrier dysfunction, & apoptosis.
The Sharma Lab uses hyperosmolar stress, benzalkonium chloride (BAC), & desiccating stress models to examine the molecular mechanisms of dry eye disease (DED) in corneal epithelial cells & mice. Our current research evaluates whether supplementation with L-carnitine, an osmoprotectant, can prevent ocular surface instability & dysfunction characteristic of DED pathology.
We collect & analyze tear fluid samples from patients and mice with & without DED.
Our research aims to identify potential biomarkers of DED through the detection of
differentially expressed microRNAs & proteins in human & mouse tears.
Funding:
Teaching:

MCG scientists secure $1.5 million grant to treat diabetic retinopathy

Noninvasive technique collects sufficient tear fluid to look for biomarkers of health and disease

Powerful anti-inflammatory molecule may block vision loss in diabetic retinopathy

$3 million National Eye Institute grant supports growth of vision research at MCG, AU


Richard Kontoh-Twumasi
706-721-3404

Graduated Students

Rebekah Robinson, MD, PhD

Arthur Miller, MD
Medical Residents & Students


Neel Edupuganti
706-731-3404
Laboratory Staff

